(Q40563060)

21 September 2017

1 reference

title

A review of the use of chemoprotectants in cancer chemotherapy (English)

1 reference

21 September 2017

C Lewis

1

1 reference

PubMed ID

7811398

21 September 2017

language of work or name

1 reference

1 September 1994

1 reference

21 September 2017

1 reference

21 September 2017

11

1 reference

21 September 2017

3

1 reference

21 September 2017

153-162

1 reference

https://scigraph.springernature.com/pub.10.2165/00002018-199411030-00002

21 September 2017

0 references

cites work

The current status of toxicity protectants in cancer therapy

1 reference

12 December 2020

Modification of some of the toxic effects of daunomycin (NSC-82,151) by pretreatment with the antineoplastic agent ICRF 159 (NSC-129,943).

1 reference

12 December 2020

Generation of free radicals of quinone group-containing anti-cancer chemicals in NADPH-microsome system as evidenced by initiation of sulfite oxidation

1 reference

12 December 2020

Risk factors for doxorubicin-induced congestive heart failure

1 reference

12 December 2020

Controlled clinical studies with an antidote against the urotoxicity of oxazaphosphorines: preliminary results

1 reference

12 December 2020

Uptake of WR-2721 derivatives by cells in culture: identification of the transported form of the drug

1 reference

12 December 2020

Hypocalcemia and Inhibition of Parathyroid Hormone Secretion after Administration of WR-2721 (a Radioprotective and Chemoprotective Agent)

1 reference

12 December 2020

Prevention of cisplatin neurotoxicity with an ACTH(4-9) analogue in patients with ovarian cancer

1 reference

12 December 2020

The effect of doxorubicin on hepatic and cardiac glutathione

1 reference

12 December 2020

Clinical trials of WR-2721 and cis-platinum

1 reference

12 December 2020

Toxicity of WR-2721 administered in single and multiple doses

1 reference

12 December 2020

Amifostine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector

1 reference

12 December 2020

ICRF-187 permits longer treatment with doxorubicin in women with breast cancer

1 reference

12 December 2020

Efficacy of the neuropeptide ORG.2766 in the prevention and treatment of cisplatin-induced neurotoxicity in rats.

1 reference

12 December 2020

Biological properties of ICRF-159 and related bis(dioxopiperazine) compounds.

1 reference

12 December 2020

Subcutaneous continuous infusion of ifosfamide and cyclophosphamide in ambulatory cancer patients: bioavailability and feasibility

1 reference

12 December 2020

A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine

1 reference

12 December 2020

Mesna side effects which imitate vasculitis

1 reference

12 December 2020

Phase I Controlled trials of WR-2721 and cyclophosphamide

1 reference

12 December 2020

Adriamycin stimulated superoxide formation in submitochondrial particles

1 reference

12 December 2020

Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer

1 reference

12 December 2020

A general mechanism for microsomal activation of quinone anticancer agents to free radicals

1 reference

12 December 2020

Factors influencing the oxidation of the radioprotector WR-1065

1 reference

12 December 2020

Chemoprotectants for cancer chemotherapy.

1 reference

12 December 2020

Pharmacokinetics of WR-2721.

1 reference

12 December 2020

Clinical trial of the effect of S-2-(3-aminopropylamino)-ethylphosphorothioic acid (WR-2721) (NSC 296961) on the toxicity of cyclophosphamide

1 reference

12 December 2020

The stability of ifosfamide in aqueous solution and its suitability for continuous 7-day infusion by ambulatory pump

1 reference

12 December 2020

The ACTH-(4-9) analog, ORG 2766, prevents taxol-induced neuropathy in rats

1 reference

12 December 2020

Stereochemistry of Intercalation: Interaction of Daunomycin with DNA

1 reference

12 December 2020

Mechanism of phospholipid peroxidation induced by ferric ion-ADP-adriamycin-co-ordination complex

1 reference

12 December 2020

Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention--III. Profile of action of sodium 2-mercaptoethane sulfonate (mesna)

1 reference

12 December 2020

Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2-(3-aminopropylamino)-ethylphosphorothioic acid

1 reference

12 December 2020

Redox cycling of anthracyclines by cardiac mitochondria. I. Anthracycline radical formation by NADH dehydrogenase.

1 reference

12 December 2020

Clinical overview of mesna

1 reference

12 December 2020

WR-2721 protects against the hematologic toxicity of cyclophosphamide: a controlled phase II trial

1 reference

12 December 2020

Phase I evaluation of ICRF-187 (NSC-169780) in patients with advanced malignancy

1 reference

12 December 2020

[Pharmacokinetics of Uromitexan]

1 reference

12 December 2020

Neurotoxic side-effects of cisplatin

1 reference

12 December 2020

Cyclophosphamide cystitis—Identification of acrolein as the causative agent

1 reference

12 December 2020

Clinical and pharmacologic investigation of the effects of alpha-tocopherol on adriamycin cardiotoxicity

1 reference

12 December 2020

ACTH accelerates recovery of neuromuscular function following crushing of peripheral nerve

1 reference

12 December 2020

Antitumor activity of 2-mercaptoethanesulfonate (mesna) in vitro. Its potential use in the treatment of superficial bladder cancer.

1 reference

12 December 2020

Role of iron in adriamycin biochemistry

1 reference

12 December 2020

Phase I trials of WR-2721 and cis-platinum

1 reference

12 December 2020

Chemical modifiers of cancer treatment

1 reference

12 December 2020

Comparison of N-acetylcysteine and mesna as uroprotectors with ifosfamide combination chemotherapy in refractory germ cell tumors

1 reference

12 December 2020

Bioavailability of orally administered mesna

1 reference

12 December 2020

Cisplatin neuropathy. Risk factors, prognosis, and protection by WR-2721.

1 reference

12 December 2020

Radioprotection of cells in culture by WR-2721 and derivatives: form of the drug responsible for protection.

1 reference

12 December 2020

Placebo-controlled double-blind comparative study on the preventive efficacy of mesna against ifosfamide-induced urinary disorders

1 reference

12 December 2020

The course of neuropathy after cessation of cisplatin treatment, combined with Org 2766 or placebo

1 reference

12 December 2020

Management of hypocalcemic effects of WR2721 administered on a daily times five schedule with cisplatin and radiation therapy. The New York Gynecologic Oncology Group

1 reference

12 December 2020

Final report of the phase I trial of single-dose WR-2721 [S-2-(3-aminopropylamino)ethylphosphorothioic acid]

1 reference

12 December 2020

10.2165/00002018-199411030-00002

Identifiers

DOI

1 reference

PubMed ID

7811398

Dimensions Publication ID

21 September 2017

0 references

1 reference

PubMed ID

7811398